{
    "organizations": [],
    "uuid": "43d8c148546e90442d0d0e80001425044ef63704",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ionis-licences-new-antisense-drug/brief-ionis-licences-new-antisense-drug-for-kidney-disease-to-astrazeneca-idUSFWN1QA0JQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Ionis Licences New Antisense Drug For Kidney Disease To Astrazeneca",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Ionis Pharmaceuticals Inc:\n* IONIS LICENCES NEW ANTISENSE DRUG FOR KIDNEY DISEASE TO ASTRAZENECA\n* IONIS PHARMACEUTICALS INC SAYS ‍IT HAS LICENSED IONIS-AZ5-2.5(RX) (AZD2373) TO GLOBAL, SCIENCE-LED BIOPHARMACEUTICAL COMPANY ASTRAZENECA​\n* IONIS PHARMACEUTICALS INC - ‍IONIS WILL RECEIVE A $30 MILLION UPFRONT PAYMENT FROM ASTRAZENECA FOR IONIS-AZ5-2.5(RX)​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-20T20:14:00.000+02:00",
    "crawled": "2018-02-21T21:36:01.015+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "ionis",
        "pharmaceutical",
        "inc",
        "ionis",
        "licence",
        "new",
        "antisense",
        "drug",
        "kidney",
        "disease",
        "astrazeneca",
        "ionis",
        "pharmaceutical",
        "inc",
        "say",
        "licensed",
        "rx",
        "azd2373",
        "global",
        "biopharmaceutical",
        "company",
        "ionis",
        "pharmaceutical",
        "inc",
        "receive",
        "million",
        "upfront",
        "payment",
        "astrazeneca",
        "rx",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}